420
Views
8
CrossRef citations to date
0
Altmetric
Review

Combination therapy for the treatment of pulmonary mold infections

, &
Pages 481-489 | Received 04 Feb 2017, Accepted 27 Apr 2017, Published online: 09 May 2017

References

  • Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41(1):60–66.
  • Riley TT, Muzny CA, Swiatlo E, et al. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother. 2016;50(9):747–757.
  • Arendrup MC, Meletiadis J, Mouton JW, et al. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin Microbiol Infect. 2016;22(6):571.e1–571.e4.
  • Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47(1):45–68.
  • Badior M, Trigo F, Eloy C, et al. Mucor infection: difficult diagnosis. Clin Drug Investig. 2013;33(Suppl 1):S19–S21.
  • Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004;10(Suppl 1):67–75.
  • Wong EH, Revankar SG. Dematiaceous molds. Infect Dis Clin North Am. 2016;30(1):165–178.
  • Mello TP, Aor AC, Gonçalves DS, et al. Assessment of biofilm formation by Scedosporium apiospermum, S. aurantiacum, S. minutisporum and Lomentospora prolificans. Biofouling. 2016;32(7):737–749.
  • Arendrup MC, Jensen RH, Cuenca-Estrella M. In Vitro Activity of ASP2397 against Aspergillus Isolates with or without acquired azole resistance mechanisms. Antimicrob Agents Chemother. 2016;60(1):532–536.
  • Enoch DA, Yang H, Aliyu SH, et al. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17–65.
  • Mariette C, Tavernier E, Hocquet D, et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leuk Lymphoma. 2016;58:1–8.
  • Emminger W, Graninger W, Emminger-Schmidmeier W, et al. Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer. Ann Hematol. 1994;68(1):27–31.
  • Prigitano A, Esposto MC, Biffi A, et al. Triazole resistance in Aspergillus fumigatus isolates from patients with cystic fibrosis in Italy. J Cyst Fibros. 2016;16:64-69.
  • Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis. 2015;61(Suppl 6):S612–S617.
  • Safdar A, Rodriguez G, Zuniga J, et al. High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events. J Pharm Pract. 2015;28(2):175–182.
  • Safdar A, Rodriguez G, Rolston KV, et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(3):157–164.
  • Anderson TM, Clay MC, Cioffi AG, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol. 2014;10(5):400–406.
  • Verweij PE, Ananda-Rajah M, Andes D, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015;21-22:30–40.
  • Dolton MJ, Perera V, Pont LG, et al. Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model. Antimicrob Agents Chemother. 2014;58(1):48–54.
  • Fournier A, Pantet O, Guerid S, et al. Effective treatment of invasive Aspergillus fumigatus infection using combinations of topical and systemic antifungals in a severely burned patient. J Burn Care Res. 2015;36(2):e85–e89.
  • Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3):e00149.
  • Meletiadis J, Pournaras S, Roilides E, et al. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 2010;54(2):602–609.
  • Nieuwenhuis S, Forstmann BU, Wagenmakers EJ. Erroneous analyses of interactions in neuroscience: a problem of significance. Nat Neurosci. 2011;14(9):1105–1107.
  • Lehár J, Zimmermann GR, Krueger AS, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol. 2007;3:80.
  • Slinker BK. The statistics of synergism. J Mol Cell Cardiol. 1998;30(4):723–731.
  • Geary N. Understanding synergy. Am J Physiol Endocrinol Metab. 2013;304(3):E237–E253.
  • Baeder DY, Yu G, Hozé N, et al. Antimicrobial combinations: bliss independence and Loewe additivity derived from mechanistic multi-hit models. Philos Trans R Soc Lond B Biol Sci. 2016;371:1695.
  • Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091–1100.
  • Rickerts V, Just-Nübling G, Konrad F, et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis. 2006;25(1):8–13.
  • Herbrecht R, Roedlich MN. Earlier diagnosis of angioinvasive pulmonary mold disease: is computed tomography pulmonary angiography a new step? Clin Infect Dis. 2012;54(5):617–620.
  • Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653.
  • Pyrgos V, Shoham S, Walsh TJ. Pulmonary zygomycosis. Semin Respir Crit Care Med. 2008;29(2):111–120.
  • Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006;173(7):707–717.
  • Denning DW, Bromley MJ. Infectious disease. How to bolster the antifungal pipeline. Science. 2015;347(6229):1414–1416.
  • Trullas JC, Cervera C, Benito N, et al. Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients. Transplant Proc. 2005;37(9):4091–4093.
  • Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107(12):2888–2897.
  • George D, Kordick D, Miniter P, et al. Combination therapy in experimental invasive aspergillosis. J Infect Dis. 1993;168(3):692–698.
  • Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003;187(12):1834–1843.
  • Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy. 2001;21(8 Pt 2):149S–164S.
  • Petraitis V, Petraitiene R, Hope WW, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother. 2009;53(6):2382–2391.
  • Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39(6):797–802.
  • Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–89.
  • Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98(2):292–299.
  • Caillot D, Thiébaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740–2746.
  • Meletiadis J, Petraitis V, Petraitiene R, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006;194(7):1008–1018.
  • Clemons KV, Parmar R, Martinez M, et al. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother. 2006;58(2):466–469.
  • Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy. 1987;33(5):381–395.
  • Hughes CE, Harris C, Moody JA, et al. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob Agents Chemother. 1984;25(5):560–562.
  • Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48(3):693–715.
  • Siopi M, Siafakas N, Vourli S, et al. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother. 2015;59(7):3973–3983.
  • Taj-Aldeen SJ, Gamaletsou MN, Rammaert B, et al. Bone and joint infections caused by mucormycetes: a challenging osteoarticular mycosis of the twenty-first century. Med Mycol. 2017.
  • Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24(2):411–445.
  • Ibrahim AS, Spellberg B, Walsh TJ, et al. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S16–S22.
  • Ibrahim AS, Spellberg B, Edwards J. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21(6):620–625.
  • Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48(12):1743–1751.
  • Spellberg B, Ibrahim A, Roilides E, et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis. 2012;54(Suppl 1):S73–S78.
  • Wang XM, Guo LC, Xue SL, et al. Pulmonary mucormycosis: a case report and review of the literature. Oncol Lett. 2016;11(5):3049–3053.
  • Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005;49(2):721–727.
  • Spellberg B, Fu Y, Edwards JE, et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49(2):830–832.
  • Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–371.
  • Kyvernitakis A, Torres HA, Jiang Y, et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016;22(9):811.e1–811.e8.
  • Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2016;102:433-444.
  • Gebremariam T, Wiederhold NP, Alqarihi A, et al. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. J Antimicrob Chemother. 2016;72:462-466.
  • Chitasombat MN, Kontoyiannis DP. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents. Curr Opin Infect Dis. 2016;29(4):340–345.
  • Ballester F, Pastor FJ, Guarro J. In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus. J Antimicrob Chemother. 2008;61(3):755–757.
  • Rodríguez MM, Serena C, Mariné M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52(10):3786–3788.
  • Lebeau O, Van Delden C, Garbino J, et al. Disseminated Rhizopus microsporus infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection. Transpl Infect Dis. 2010;12(3):269–272.
  • Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am. 2016;30(1):143–163.
  • Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–e130.
  • van Diepeningen AD, Brankovics B, Iltes J, et al. Diagnosis of fusarium infections: approaches to identification by the Clinical Mycology Laboratory. Curr Fungal Infect Rep. 2015;9(3):135–143.
  • McCarthy M, Rosengart A, Schuetz AN, et al. Mold infections of the central nervous system. N Engl J Med. 2014;371(2):150–160.
  • Montejo M, Muñiz ML, Zárraga S, et al. Case reports. Infection due to Scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by Pseudallescheria boydii/Sc. apiospermum. Mycoses. 2002;45(9–10):418–427.
  • Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21(1):157–197.
  • Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54(10):4446–4450.
  • Nucci M, Marr KA, Vehreschild MJ, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6):580–585.
  • Steinberg GK, Britt RH, Enzmann DR, et al. Fusarium brain abscess. Case report. J Neurosurg. 1983;58(4):598–601.
  • Tupaki-Sreepurna A, Al-Hatmi AM, Kindo AJ, et al. Multidrug-resistant Fusarium in keratitis: a clinico-mycological study of keratitis infections in Chennai, India. Mycoses. 2016;60:230-233.
  • Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20(4):695–704.
  • Martino P, Gastaldi R, Raccah R, et al. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect. 1994;28(Suppl 1):7–15.
  • Rabodonirina M, Piens MA, Monier MF, et al. Fusarium infections in immunocompromised patients: case reports and literature review. Eur J Clin Microbiol Infect Dis. 1994;13(2):152–161.
  • Anaissie E, Paetznick V, Proffitt R, et al. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis. 1991;10(8):665–668.
  • Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90(3):999–1008.
  • Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am. 1996;10(2):365–400.
  • Nucci F, Nouér SA, Capone D, et al. Fusariosis. Semin Respir Crit Care Med. 2015;36(5):706–714.
  • Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122–1131.
  • Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45(Suppl 3):56–60.
  • Córdoba S, Rodero L, Vivot W, et al. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 2008;31(2):171–174.
  • Blyth CC, Middleton PG, Harun A, et al. Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? Med Mycol. 2010;48(Suppl 1):S37–S44.
  • Han Z, Kautto L, Nevalainen H. Secretion of proteases by an opportunistic fungal pathogen scedosporium aurantiacum. PLoS One. 2017;12(1):e0169403.
  • Gruber M, Moser I, Nagl M, et al. Bactericidal and fungicidal activity of N-chlorotaurine is enhanced in cystic fibrosis sputum medium. Antimicrob Agents Chemother. 2017.
  • Koga T, Kitajima T, Tanaka R, et al. Chronic pulmonary scedosporiosis simulating aspergillosis. Respirology. 2005;10(5):682–684.
  • Rahman FU, Irfan M, Fasih N, et al. Pulmonary scedosporiosis mimicking aspergilloma in an immunocompetent host: a case report and review of the literature. Infection. 2016;44(1):127–132.
  • Kim SH, Ha YE, Youn JC, et al. Fatal scedosporiosis in multiple solid organ allografts transmitted from a nearly-drowned donor. Am J Transplant. 2015;15(3):833–840.
  • Taylor A, Talbot J, Bennett P, et al. Disseminated Scedosporium prolificans infection in a Labrador retriever with immune mediated haemolytic anaemia. Med Mycol Case Rep. 2014;6:66–69.
  • Hartmann C, Müller C, Weißbrodt H, et al. Successful prevention of scedosporiosis after lung transplantation in a cystic fibrosis patient by combined local and systemic triazole therapy. Med Mycol Case Rep. 2013;2:116–118.
  • Holmes NE, Trevillyan JM, Kidd SE, et al. Locally extensive angio-invasive Scedosporium prolificans infection following resection for squamous cell lung carcinoma. Med Mycol Case Rep. 2013;2:98–102.
  • Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006;50(3):917–921.
  • Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42(6):741–745.
  • Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55(10):4652–4658.
  • Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52(4):1396–1400.
  • Espinel-Ingroff A, Johnson E, Hockey H, et al. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother. 2008;61(3):616–620.
  • Halliday CL, Chen SC, Kidd SE, et al. Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations. Int J Antimicrob Agents. 2016;48(4):453–458.
  • Lackner M, Hagen F, Meis JF, et al. Susceptibility and diversity in the therapy-refractory genus scedosporium. Antimicrob Agents Chemother. 2014;58(10):5877–5885.
  • Heyn K, Tredup A, Salvenmoser S, et al. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother. 2005;49(12):5157–5159.
  • Safdar A. Fungal cytoskeleton dysfunction or immune activation triggered by beta-glucan synthase inhibitors: potential mechanisms for the prolonged antifungal activity of echinocandins. Cancer. 2009;115(13):2812–2815.
  • Steinbach WJ, Schell WA, Miller JL, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41(8):3981–3985.
  • Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52(5):1743–1750.
  • Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis. 2005;40(Suppl 6):S401–S408.
  • Capilla J, Mayayo E, Serena C, et al. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. J Antimicrob Chemother. 2004;54(6):1092–1095.
  • Naggie S, Perfect JR. Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis. Clin Chest Med. 2009;30(2):337–353, vii–viii.
  • Al-Tawfiq JA, Boukhamseen A. Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): case presentation and literature review. J Infect Public Health. 2011;4(2):96–102.
  • Ben-Ami R, Lewis RE, Raad II, et al. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis. 2009;48(8):1033–1041.
  • Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis. 2004;38(2):206–216.
  • O’Shea PM, Griffin TP, Fitzgibbon M. Hypertension: the role of biochemistry in the diagnosis and management. Clin Chim Acta. 2016;18:31-37.
  • Weiss A, Nowak-Sliwinska P. Current trends in multidrug optimization. J Lab Autom. 2016;10:2472630316682338.
  • Frigati L, Wynberg E, Maritz J, et al. Antiretroviral treatment initiated in the first month of life. Pediatr Infect Dis J. 2016;36:110-120.
  • Albertson TE, Bullick SW, Schivo M, et al. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Drug Des Devel Ther. 2016;10:4047–4060.
  • Steinbach WJ. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord. 2005;5(3):203–210.
  • Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.
  • Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005;18(1):163–194.
  • Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections. Virulence. 2017;8(2):169–185.
  • Candoni A, Aversa F, Busca A, et al. Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. J Chemother. 2015;27(1):1–12.
  • Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter. 2013;26(2):173–188.
  • Martin-Vicente A, Capilla J, Guarro J. Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis. Med Mycol. 2016.
  • Yao L, Wan Z, Li R, et al. In vitro triple combination of antifungal drugs against clinical scopulariopsis and microascus species. Antimicrob Agents Chemother. 2015;59(8):5040–5043.
  • Wilson DT, Dimondi VP, Johnson SW, et al. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016;12:1197–1206.
  • Kovanda LL, Maher R, Hope WW. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Rev Clin Pharmacol. 2016;9(7):887–897.
  • Townsend R, Dietz A, Hale C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2016;6:44-53.
  • Walker RC, Zeuli JD, Temesgen Z. Isavuconazonium sulfate for the treatment of fungal infection. Drugs Today (Barc). 2016;52(1):7–16.
  • Cornely OA, Böhme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078–2085.
  • Katragkou A, McCarthy M, Meletiadis J, et al. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds. Antimicrob Agents Chemother. 2014;58(11):6934–6937.
  • Osherov N, Kontoyiannis DP. The anti-Aspergillus drug pipeline: is the glass half full or empty? Med Mycol. 2016;55:118-124.
  • Shibata T, Takahashi T, Yamada E, et al. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother. 2012;56(11):5892–5897.
  • Watanabe NA, Miyazaki M, Horii T, et al. Hata K. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother. 2012;56(2):960–971.
  • Compain F, Botterel F, Sitterlé E, et al. In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp. J Med Microbiol. 2015;64(Pt 3):309–311.
  • Trubiano JA, Paratz E, Wolf M, et al. Disseminated Scedosporium prolificans infection in an ‘extensive metaboliser’: navigating the minefield of drug interactions and pharmacogenomics. Mycoses. 2014;57(9):572–576.
  • Kesson AM, Bellemore MC, O’Mara TJ, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis. 2009;48(9):1257–1261.
  • Martin-Vicente A, Guarro J, Capilla J. Does a triple combination have better activity than double combinations against multiresistant fungi? Experimental in vitro evaluation. Int J Antimicrob Agents. 2017;49:422-426.
  • Panackal AA. Combination antifungal therapy for invasive aspergillosis revisited. Med Mycol Open Access. 2016;2:2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.